New drugs to relieve cancer pain

Jun 21, 2010

Researchers at the University of Leicester and the University of Ferrara in Italy have collaborated to develop new drugs which have the potential to relieve cancer pain without causing many of the side effects of current pain-treatments like morphine.

Figures show that 90% of patients experience pain in the final year of their lives and this is a big problem. Currently, the use of drugs like morphine produces such as depressed breathing, drowsiness, constipation and tolerance. Unfortunately tolerance usually results in an increased dose of morphine, which in turn means that patients experience more of these side effects.

Professors David Lambert and David Rowbotham at the University of Leicester, as well as Doctors Guerrini, Calo and Professor Salvadori from the University of Ferrara in Italy, are leading the early experiments of a new group of drugs which may not produce these side effects. The research done at the University of Leicester has been funded by the Leicestershire and Rutland charity Hope Against Cancer.

Professor David Lambert commented:

"This work is still at a very early stage but has the potential to change the way we think about making drugs for pain related issues."

The new group of drugs, which were developed in the University of Ferrara and tested by the University of Leicester, is designed to produce by acting at two targets simultaneously. The two target idea may provide effective pain relief with less tolerance.

Hope Against Cancer has funded this 3-year PhD project at the University of Leicester to look at the long term effects of these new drugs, with a primary focus on drug tolerance.

Nikolaos Dietis, the PhD research student who is currently working on the project, said:

"Tolerance to strong like morphine involves complicated biological processes, aspects of which still remain questionable. Our research may provide some answers by designing new drugs that have multiple roles. We are now studying these drugs to see what they do in the long-term."

Dr Guerrini said:

"Pain is a very complicated condition, whose control and relief could be achieved with the use of drugs that act on two different targets in order to obtain pain relief more effectively."

The project at the University of Leicester could lead to further development of these new drugs that could even lead to future trials on cancer patients.

Professor Rowbotham commented:

"We need to further refine this work to enable studies to be performed in patients. This may be a relatively long-term process, but it offers a completely new approach to pain management for cancer patients in the future."

Explore further: Acne pill benefits outweigh blood clot risk: EU agency

add to favorites email to friend print save as pdf

Related Stories

Researchers show how morphine can be given more effectively

Apr 27, 2009

Researchers at the Hebrew University of Jerusalem have found a way to maintain the pain-killing qualities of morphine over an extended period of time, thus providing a solution for the problem of having to administer increasing ...

Scientist Unraveling Mystery of Treating Chronic Pain

Sep 14, 2009

(PhysOrg.com) -- Successfully treating chronic pain with opioids such as morphine -- minus the side effects -- may soon become a reality, bringing relief to millions of people who suffer from debilitating ...

Morphine dependency blocked by single genetic change

Jan 28, 2008

Morphine’s serious side effect as a pain killer – its potential to create dependency – has been almost completely eliminated in research with mice by genetically modifying a single trait on the surface of neurons. The ...

Recommended for you

First influenza vaccine brought to clinical testing

May 17, 2013

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Aspirin not always best treatment for many individuals

May 16, 2013

(Medical Xpress)—An aspirin a day may not always keep heart disease away, say two University of Florida cardiologists. But a new algorithm they have developed outlines factors physicians should weigh as ...

FDA: lower ambien's dose to prevent drowsy driving

May 15, 2013

(HealthDay)—The U.S. Food and Drug Administration has approved new, lower-dose labeling for the popular sleep drug Ambien (zolpidem) in an effort to cut down on daytime drowsiness that could be a hazard ...

Simponi approved for ulcerative colitis

May 15, 2013

(HealthDay)—Simponi (golimumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with moderate-to-severe ulcerative colitis.

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

User comments : 0

More news stories

US psychiatry gets makeover in new manual

The latest makeover to a massive psychiatric tome honored by some, reviled by others and even called the "Bible" of mental disorders is being released Saturday with a host of new changes.

New case of SARS-like virus in Saudi: ministry

A new case of the deadly coronavirus has been detected in Saudi Arabia where 15 people have already died after contracting it, the health ministry announced on Saturday on its Internet website.

New colonoscope provides ground-breaking view of colon

A ground-breaking advance in colonoscopy technology signals the future of colorectal care, according to research presented today at Digestive Disease Week(DDW). Additional research focuses on optimizing the minimal withdrawal ...

Galaxy's Ring of Fire

Johnny Cash may have preferred this galaxy's burning ring of fire to the one he sang about falling into in his popular song. The "starburst ring" seen at center in red and yellow hues is not the product of ...

US seizes Bitcoin operator accounts

US authorities seized the accounts of a Bitcoin digital currency exchange operator, claiming it was functioning as an "unlicensed money service business," court documents showed Friday.